Studies on the hepatic localization of A‐FABP using specimen of NASH patients and the correlation of A‐FABP expression to the LSEC capillarization and the severity of liver fibrosis in NASH may provide clinical relevance of the current findings. Here, FABP4 is linked to metabolic dysfunction-associated steatohepatitis.